Public articles linked to the same research event.
medRxiv This study updated an automated tumour infiltrating lymphocyte (TIL) assessment pipeline, proposing TRIGS aligned with clinical scoring guidelines and foundation model-based SAM-TIL, and showed in 166 neoadjuvantly treated patients in the TransNEO cohort that they predicted pathological complete response with odds ratios of 1.95 (95% CI 1.22-3.03, p=0.005) and 2.32 (95% CI 1.43-3.77, p=0.001), and in 277 triple negative and HER2-positive patients in The Cancer Genome Atlas showed overall survival hazard ratios of 0.79 (95% CI 0.63-1.00, p=0.05) and 0.80 (95% CI 0.67-0.97, p=0.02), with correlation to gold standard clinical assessment of 0.59-0.69 and no substantial difference from gold standard assessment in predicting pathological complete response (AUC 0.60-0.
This study updated an automated tumour infiltrating lymphocyte (TIL) assessment pipeline, proposing TRIGS aligned with clinical scoring guidelines and foundation model-based SAM-TIL, and showed in 166 neoadjuvantly treated patients in the TransNEO cohort that they predicted pathological complete response with odds ratios of 1.95 (95% CI 1.22-3.03, p=0.005) and 2.32 (95% CI 1.43-3.77, p=0.001), and in 277 triple negative and HER2-positive patients in The Cancer Genome Atlas showed overall survival hazard ratios of 0.79 (95% CI 0.63-1.00, p=0.05) and 0.80 (95% CI 0.67-0.97, p=0.02), with correlation to gold standard clinical assessment of 0.59-0.69 and no substantial difference from gold standard assessment in predicting pathological complete response (AUC 0.60-0.
This study updated an automated tumour infiltrating lymphocyte (TIL) assessment pipeline, proposing TRIGS aligned with clinical scoring guidelines and foundation model-based SAM-TIL, and showed in 166 neoadjuvantly treated patients in the TransNEO cohort that they predicted pathological complete response with odds ratios of 1.95 (95% CI 1.22-3.03, p=0.005) and 2.32 (95% CI 1.43-3.77, p=0.001), and in 277 triple negative and HER2-positive patients in The Cancer Genome Atlas showed overall survival hazard ratios of 0.79 (95% CI 0.63-1.00, p=0.05) and 0.80 (95% CI 0.67-0.97, p=0.02), with correlation to gold standard clinical assessment of 0.59-0.69 and no substantial difference from gold standard assessment in predicting pathological complete response (AUC 0.60-0.
This study updated an automated tumour infiltrating lymphocyte (TIL) assessment pipeline, proposing TRIGS aligned with clinical scoring guidelines and foundation model-based SAM-TIL, and showed in 166 neoadjuvantly treated patients in the TransNEO cohort that they predicted pathological complete response with odds ratios of 1.95 (95% CI 1.22-3.03, p=0.005) and 2.32 (95% CI 1.43-3.77, p=0.001), and in 277 triple negative and HER2-positive patients in The Cancer Genome Atlas showed overall survival hazard ratios of 0.79 (95% CI 0.63-1.00, p=0.05) and 0.80 (95% CI 0.67-0.97, p=0.02), with correlation to gold standard clinical assessment of 0.59-0.69 and no substantial difference from gold standard assessment in predicting pathological complete response (AUC 0.60-0.